The Competition and Markets Authority is in charge of promoting competition and reducing anti-competitive activities in the UK.
To help fund the acquisition, Yourgene Health is planning to sell at least £10.0 million in newly issued shares to institutional investors.
The firm originally raised $55.5 million in the round in February 2018, and said investors added $30 million in December and another $20 million more recently.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.
The acquisition will result in a new DLS division called HudsonAlpha Discovery that will provide a range of services to the pharma, biotech, and diagnostics industries.
Under the agreement, Bellwether researchers will join the team advancing Guardant's LUNAR early cancer detection and monitoring assays.
The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
DermTech develops diagnostics for skin cancer and other skin diseases, and provides molecular pathology services through its CLIA-certified lab.
The firm said the purchase will allow it to better provide software tools to customers in the chemistry, pharmaceutical, and analytical laboratory markets.
Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.